Skip to content
LexBuild

Schedule for Rating Disabilities; The Skin

---
identifier: "/us/fr/02-25492"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Schedule for Rating Disabilities; The Skin"
title_number: 0
title_name: "Federal Register"
section_number: "02-25492"
section_name: "Schedule for Rating Disabilities; The Skin"
positive_law: false
currency: "2002-10-09"
last_updated: "2002-10-09"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Veterans Affairs Department"
document_number: "02-25492"
document_type: "rule"
publication_date: "2002-10-09"
agencies:
  - "Veterans Affairs Department"
cfr_references:
  - "38 CFR Part 36"
rin: "2900-AF00"
fr_citation: "67 FR 62889"
fr_volume: 67
effective_date: "2002-07-31"
fr_action: "Final rule; correction."
---

#  Schedule for Rating Disabilities; The Skin

**AGENCY:**

Department of Veterans Affairs.

**ACTION:**

Final rule; correction.

**SUMMARY:**

In a document published in the *Federal Register* on July 31, 2002, (67 FR 49590), we amended that portion of the Department of Veterans Affairs (VA) Schedule for Rating Disabilities that addresses the skin. The document contains an error in the Supplementary Information portion of the preamble. That error consists of an incorrect restatement of regulatory text. This document corrects that error.

**DATES:**

*Effective Date:* This correction is effective July 31, 2002.

**FOR FURTHER INFORMATION CONTACT:**

Caroll McBrine, M.D., Consultant, Policy and Regulations Staff (211B), Compensation and Pension Service, Veterans Benefits Administration, Department of Veterans Affairs, 810 Vermont Avenue NW., Washington, DC 20420, (202) 273-7230.

**SUPPLEMENTARY INFORMATION:**

In rule FR Doc. 02-19331, published on July 31, 2002 (67 FR 49590), on page 49595, in column 1, the first paragraph, the phrase “a 30-percent evaluation calls for recurrent debilitating episodes at least four times during the past 12-month period despite ongoing immunosuppressive therapy” is corrected to read “a 30-percent evaluation calls for recurrent debilitating episodes at least four times during the past 12-month period, and requiring intermittent systemic immunosuppressive therapy.”

Roland Halstead,

Acting Director, Office of Regulatory Law.